SCHEMBL13411367

SCHEMBL13411367

CCOC(=O)[C@@H]1CC2(CCCO2)CC[C@@H]1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 5/20 0.34
OPRM1 P35372 2/20 0.34
OPRD1 P41143 2/20 0.34
TP53 P04637 2/20 0.34
CYP3A4 P08684 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
THRB P10828 1/20 0.34
MTOR P42345 1/20 0.34
BLM P54132 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CYP2D6 P10635 1/20 0.34
ALOX15 P16050 1/20 0.34
NFKB1 P19838 1/20 0.34
ALDH1A1 P00352 2/20 0.34
PPM1B O75688 1/20 0.33
PTPN1 P18031 1/20 0.33
PPP1CC P36873 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9729278 0.81 CYP3A4 (0.37) TP53CYP3A4KDM4ELMNACYP2D6
SCHEMBL12598334 0.81 CYP3A4 (0.37) TP53CYP3A4KDM4ELMNACYP2D6
SCHEMBL12156499 0.81 CYP3A4 (0.37) TP53CYP3A4KDM4ELMNACYP2D6
SCHEMBL9729287 0.81 CYP3A4 (0.37) TP53CYP3A4KDM4ELMNACYP2D6
SCHEMBL13411394 0.81 CYP3A4 (0.37) TP53CYP3A4KDM4ELMNACYP2D6
SCHEMBL9728986 0.81 CYP3A4 (0.37) TP53CYP3A4KDM4ELMNACYP2D6
SCHEMBL12144976 0.80 ALDH1A1 (0.33) OPRK1OPRM1OPRD1TP53CYP3A4
Bromide SCHEMBL1770016 0.80 CYP3A4 (0.36) TP53CYP3A4LMNACYP2D6ALDH1A1
SCHEMBL7878595 0.79 ALDH1A1 (0.41) OPRK1OPRM1OPRD1TP53CYP3A4
SCHEMBL22898114 0.77 ALDH1A1 (0.44) TP53CYP3A4CYP2D6ALDH1A1PPM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671062-B2 Modulators of chemokine receptor activity, crystalline forms and process BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-02 US disclosed
US-20080027083-A1 MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS BRISTOL-MYERS SQUIBB COMPANY 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027083-A1 MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CRYSTALLINE FORMS AND PROCESS ACKR3, CCR1, CCR2 OPRK1 252/4885OPRM1 337/4885OPRD1 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.